Tubulis GmbH’s Post

Clarivate released the 2024 Companies to Watch report, highlighting seven innovative companies advancing antibody drug conjugates (ADCs) to deliver highly targeted cancer treatments with minimal side effects. The companies - Adcendo, Araris Biotech AG, GO Therapeutics, Heidelberg Pharma AG, Pheon Therapeutics, Tallac Therapeutics, Tubulis GmbH – are transforming drug discovery and development, revolutionizing cancer treatment, and capturing big pharma interest. The report, based on data from BioWorld News and an analysis of drug benefits, financing, and R&D activity, explains why these companies are significant innovators. "Data reveals a clear trend: Big Pharma is swiftly integrating ADCs into their portfolios through partnerships and acquisitions. ADCs are rapidly maturing in the clinical space, expanding beyond oncology into diverse therapeutic areas” quotes Mike Ward, Global Head of Life Sciences and Healthcare Thought Leadership at Clarivate. Read more: https://lnkd.in/ezuGNPBk #oncology #cancertreatment #drugdiscovery #pharma

Today Clarivate announced its annual Companies to Watch report, highlighting seven innovative companies revolutionizing drug discovery and development. These companies are advancing antibody-drug conjugates (ADCs) to deliver highly targeted cancer treatments with minimal side effects. Based on data, insights and analysis of drug benefits, financing and R&D activity, the report explores why these companies are significant innovators.    You can download the report, here: Companies to Watch: Antibody Drug Conjugates - Clarivate

Latest Life Science News / Updates : 📌 Regeneron is committing up to $500 million over the next five years for its new private financing arm. 📌 Clario has purchased ArtiQ, an artificial intelligence software developer that creates AI solutions for diagnosing and treating patients with respiratory disease. 📌 Genmab announces acquisition of ProfoundBio for $1.8 billion 📌 Obsidian Therapeutics has raised $160 million in a series C. 📌 Alterome Therapeutics, Inc Therapeutics has closed a $132 million series B, cash that will go toward the development of next-gen, small molecule targeted oncology therapies. 📌 Diagonal Therapeutics has raised $128 million to advance its antibody agonist-building platform. 📌 Boundless Bio is bringing in $100 million from its IPO as the precision oncology company becomes the latest biotech to go public in 2024. 📌 Lonza have appointed new CEO - Wolfgang Wienand

🤝 Exciting Collaboration Alert! AstraZeneca joins forces with U.S. AiBIOLOGICS firm Absci in a deal valued up to $247 million to design a cutting-edge antibody for cancer treatment! 🌐💊 🔬 Absci's generative AI model, powered by artificial intelligence, aims to revolutionise antibody therapeutics, bringing innovation to oncology treatments. 🎯🤖 👨💼 Absci CEO Sean McClain expresses pride in leveraging AI to develop novel treatments for oncology patients in collaboration with AstraZeneca. 👉 AstraZeneca, a global pharmaceutical leader, continues to push the boundaries of innovation in the fight against cancer. 📰 The Financial Times reports that the deal includes an upfront fee, research and development funding, milestone payments, and royalties on product sales. #AstraZeneca #Absci #AIinBiologics #CancerTreatment #InnovationInOncology 💡👥 #BiotechCollaboration #AIInHealthcare #CancerResearch #PharmaInnovation 🌐💉

Third Arc Bio originally sought $100 million for its Series A, but with a star-studded executive team that has brought more than 15 new medicines to market, the biotech ended up reeling in $165 million. Founded by Johnson & Johnson veteran Sanjaya Singh and led by former J&J global oncology leader Peter Lebowitz, the Philadelphia-area startup will test its multispecific antibodies in solid tumors and I&I conditions starting next year. Its Series A includes many crossover and public investors, giving the nascent company multiple options before its capital runs dry in roughly three years. “At J&J, I saw all the platforms. We had them all. I specifically wanted to work on [multispecific antibodies] because this is the area where there is the largest opportunity to meet unmet need,” Lebowitz said in an interview with Endpoints News. “There’s a lot of interest in ADCs now, and ADCs are very important. But this is the area that is right in the right spot of the breaking point where it goes over the edge and actually is transformational for solid tumors.” #biotech #venturecapital #biotechvc #thirdarc #biologics #multispecificantibodies #solidtumors #autoimmune #immunology #drugdevelopment

Delighted to have the attended the first official General Assembly meeting of the PSCC Connect network, part of the Paris Saclay Cancer Cluster, this afternoon. I enjoyed hearing the PSCC team explain the working structure, budget and future plans of the network, meeting fellow members and hearing elevator pitches from 20 Oncology start-ups, encompassing ADCs (MIO / McSAF), Biologics (ABCELY), Small-Molecule Drugs (Promontory Therapeutics), Cell Therapies (PERSEA), Anti-Cancer Vaccines (Brenus Pharma, ErVimmune), Drug Repurposing (PEGASCY) and various other domains (HEPHAISTOS-Pharma and so many others...). Photo: various attendees. Inset: Gregory Qushair (Alésia Consulting) with Wahid Awad, Ph.D. MBA (Rosetta Omics). ABCELYARDAN PHARMA Serendip innovations Apmonia Therapeutics Exosome Analytics GIMLI Jalon Therapeutics MSInsight PepKon #oncology #biotechnology #pharmaceuticals #diagnostics #cancer #paris #drugdiscovery #celltherapy #immunotherapy #omics

Triple Negative Breast Cancer (TNBC) Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Merck, Roche, Tesaro, Clovis, Gilead #Finance #FinancialMarket #MarketingSales #PharmaceuticalsBiotech

Boldly going ...to tackle the 'high-hanging fruit in oncology." More oncology pipeline developments from Merck; this as it relates to the potential of macrocyclic peptides coupled with AI platforms through a collaboration partnership with California-based Unnatural Products Inc. (UNP). "UNP is working on a new approach centered on macrocycles and cyclic peptides, designed through its AI-driven platform, to address traditionally hard-to-reach intracellular targets. The compounds may help expand the druggable genome by hitting targets that are otherwise too complex for small molecules, or replicating the potency and selectivity of antibodies, but in an oral dosage form." https://lnkd.in/eKEpcP7M #Merck #MerckResearchLabs #Oncology #UnnaturalProducts #Biotech #Innovation #TargetedTherapies #IntracellularTargeting #Pharma #Healthcare